Pressure BioSciences, Inc.

OTCPK:PBIO Stock Report

Market Cap: US$4.4m

Pressure BioSciences Past Earnings Performance

Past criteria checks 0/6

Pressure BioSciences's earnings have been declining at an average annual rate of -8.1%, while the Life Sciences industry saw earnings growing at 16.8% annually. Revenues have been declining at an average rate of 1.2% per year.

Key information

-8.1%

Earnings growth rate

45.1%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate-1.2%
Return on equityn/a
Net Margin-1,779.9%
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Pressure BioSciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:PBIO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 232-3591
30 Sep 232-3061
30 Jun 232-2861
31 Mar 232-2061
31 Dec 222-1841
30 Sep 221-1741
30 Jun 222-1941
31 Mar 222-2041
31 Dec 212-2341
30 Sep 212-2341
30 Jun 212-2141
31 Mar 212-2041
31 Dec 201-1841
30 Sep 201-1752
30 Jun 201-1852
31 Mar 202-1751
31 Dec 192-1651
30 Sep 192-1750
30 Jun 192-1650
31 Mar 192-2550
31 Dec 182-2340
30 Sep 182-2140
30 Jun 182-2040
31 Mar 182-750
31 Dec 172-1150
30 Sep 172-550
30 Jun 172-440
31 Mar 172-340
31 Dec 162-340
30 Sep 162-1040
30 Jun 162-1040
31 Mar 162-1040
31 Dec 152-740
30 Sep 152-530
30 Jun 152-530
31 Mar 151-530
31 Dec 141-630
30 Sep 141-730
30 Jun 141-630
31 Mar 142-730
31 Dec 132-530
30 Sep 131-430

Quality Earnings: PBIO is currently unprofitable.

Growing Profit Margin: PBIO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PBIO is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.

Accelerating Growth: Unable to compare PBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PBIO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.5%).


Return on Equity

High ROE: PBIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.